round button
Leave a message

Global Geographic Atrophy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Geographic Atrophy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Pharmaceutical
  • Upcoming Report
  • Dec 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Geographic Atrophy Market

Market Size in USD Billion

CAGR :  % Diagram

Chart Image USD 1.78 Billion USD 3.80 Billion 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size (Base Year)
USD 1.78 Billion
Diagram Market Size (Forecast Year)
USD 3.80 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Geographic Atrophy Market Segmentation, By Drug Class (Anti-VEGF (Vascular Endothelial Growth Factor) Agents, Complement Pathway Inhibitors, Cell and Gene Therapies, Other Therapeutics), Route of Administration (Intravitreal, Oral, Others), Gender (Male, Female), End User (Hospitals, Ophthalmic Clinics, Homecare Settings), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Industry Trends and Forecast to 2032

Geographic Atrophy Market

Geographic Atrophy Market Analysis

The Global Geographic Atrophy (GA) Market is driven by the increasing prevalence of age-related macular degeneration (AMD), of which GA is an advanced form. According to the BrightFocus Foundation, approximately 196 million people worldwide are affected by AMD, with an estimated 10-15% progressing to GA. The prevalence of GA significantly increases with age, impacting nearly 5% of individuals over 75 years old in developed regions like the U.S. and Europe. Advances in diagnostic imaging, such as Optical Coherence Tomography (OCT), have improved early detection rates, allowing for timely intervention. Additionally, the market is bolstered by rising awareness of GA among aging populations and ongoing research into innovative therapies targeting the complement pathway and neuroprotection. However, the lack of curative treatments remains a critical challenge, underscoring the urgent need for novel therapeutic developments.

Geographic Atrophy Market Size

Global geographic atrophy market size was valued at USD 1.78 billion in 2024 and is projected to reach USD 3.80 billion by 2032, with a CAGR of 9.60% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Geographic Atrophy Market Trends

“Rising Adoption of Intravitreal Injections”

The adoption of intravitreal injections is increasingly becoming the standard for administering therapies in the treatment of Geographic Atrophy (GA). This method ensures that medications are delivered directly to the retina, allowing for localized treatment with minimal systemic exposure, which reduces the risk of adverse side effects. Advancements in injection delivery techniques, such as fine-gauge needles and optimized injection protocols, have improved the overall safety and comfort of the procedure. Additionally, innovations in sustained-release formulations are helping to reduce the frequency of injections, enhancing adherence among patients, particularly in elderly populations who may face challenges with frequent clinical visits.

Report Scope and Geographic Atrophy Market Segmentation

Attributes

Global Geographic Atrophy Key Market Insights

Segments Covered

  • By Drug Class: Anti-VEGF (Vascular Endothelial Growth Factor) Agents, Complement Pathway Inhibitors, Cell and Gene Therapies, Other Therapeutics
  • By Route of Administration: Intravitreal, Oral, Others
  • By Gender: Male, Female
  • By End User: Hospitals, Ophthalmic Clinics, Homecare Settings
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Countries Covered

U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America

Key Market Players

Apellis Pharmaceuticals, Inc. (U.S.), Regeneron Pharmaceuticals, Inc.  (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Biogen Inc. (U.S.), Gyroscope Therapeutics Limited (UK), Kodiak Sciences Inc. (U.S.), Lineage Cell Therapeutics, Inc. (U.S.), AbbVie Inc. (U.S.), Outlook Therapeutics, Inc. (U.S.), Iveric Bio, Inc. (U.S.), Astellas Pharma Inc. (Japan), Adverum Biotechnologies, Inc. (U.S.), Alkeus Pharmaceuticals, Inc. (U.S.), Annexon, Inc. (U.S.), Nanoscope Therapeutics, Inc. (U.S.), Clearside Biomedical, Inc. (U.S.), ReNeuron Group plc (UK), and Ocugen, Inc. (U.S.) among others.

Market Opportunities

  • Expansion of Personalized Treatment Approaches
  • Increased Public Awareness and Early Detection Programs

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Geographic Atrophy Market Definition

Geographic Atrophy (GA) is an advanced, progressive form of age-related macular degeneration (AMD) characterized by the gradual loss of retinal cells, including photoreceptors, retinal pigment epithelium (RPE), and choriocapillaris. This degeneration leads to the formation of well-demarcated atrophic lesions in the macula, resulting in severe and irreversible vision loss over time. GA primarily affects central vision, significantly impairing tasks like reading and recognizing faces, and is most common in individuals aged 50 years and older.

Geographic Atrophy Market Dynamics

Drivers  

  • Increasing Prevalence of Age-Related Macular Degeneration (AMD)

The increasing prevalence of age-related macular degeneration (AMD) is a key factor contributing to the growth of the Geographic Atrophy (GA) market. AMD, a leading cause of vision loss among individuals aged 50 and older, affects approximately 196 million people globally, with the number expected to reach 288 million by 2040 due to aging populations. GA, the advanced, irreversible stage of AMD, significantly impairs central vision, affecting activities such as reading and face recognition. As the global elderly population continues to expand, particularly in developed regions like North America and Europe, the incidence of AMD and subsequent progression to GA are expected to rise. This growing patient base has intensified the demand for improved diagnostic tools and innovative therapies to manage the disease. Enhanced awareness and regular eye screening programs further support early detection, while ongoing research focuses on addressing the unmet clinical needs of this vulnerable population​.  

  • Advancements in Complement Pathway-Based Therapies   

Advancements in complement pathway-based therapies are transforming the treatment landscape for Geographic Atrophy (GA). The complement system, a critical component of the immune response, plays a pivotal role in the progression of GA, particularly through overactivation that damages retinal cells. Therapies targeting this pathway aim to slow disease progression by inhibiting specific complement factors such as C3 and C5. Pegcetacoplan, a complement C3 inhibitor, has shown promise in clinical trials, reducing the growth rate of atrophic lesions in GA patients. Other complement inhibitors under development are further expanding the therapeutic pipeline. These breakthroughs address the lack of effective treatments for GA, offering hope for improved management and quality of life for affected individuals. The success of such therapies is driving increased research funding and collaborations in the biopharmaceutical sector, underscoring their potential to meet a significant unmet need in ophthalmology.

Opportunities

  • Expansion of Personalized Treatment Approaches

The expansion of personalized treatment approaches presents a significant opportunity in the Global Geographic Atrophy (GA) market as our understanding of the genetic and molecular mechanisms driving the disease continues to grow. By leveraging advanced diagnostics, such as genetic screening and the identification of specific biomarkers, treatments can be tailored to the unique characteristics of individual patients. This approach allows for the selection of therapies that are more likely to be effective, based on the patient's genetic makeup and the underlying causes of their condition. Personalized medicine could also help minimize side effects by targeting the root causes of GA more precisely, leading to safer and more efficient treatment options. Additionally, by providing treatments that are better suited to each patient, personalized approaches may improve adherence to treatment regimens, enhancing overall therapeutic outcomes. As a result, personalized treatments are expected to be a major growth driver in the Geographic Atrophy market.

  • Increased Public Awareness and Early Detection Programs

Increased public awareness and early detection programs are key factors driving growth in the Global Geographic Atrophy (GA) market. As awareness of GA and its early symptoms, such as vision distortion or blind spots, rises, individuals are more likely to seek early medical attention, leading to quicker diagnoses. Early detection enables the initiation of treatment at earlier disease stages, which can help slow the progression of GA and preserve vision for a longer period, improving patient outcomes. Additionally, widespread awareness encourages individuals, especially those in higher-risk age groups, to undergo regular eye exams and screenings, further promoting early diagnosis. This growing focus on early intervention has also sparked greater investment in advanced diagnostic technologies and innovative treatment options, as stakeholders recognize the potential for improving patient care. Ultimately, public education and screening programs are crucial in reducing the burden of GA while boosting demand for targeted therapies and diagnostic tools.

Restraints/Challenges

  • High Treatment Costs

High treatment costs are a significant restraint on the Global Geographic Atrophy (GA) market. Many of the emerging therapies, such as complement inhibitors and gene therapies, come with considerable expenses, which can make them out of reach for a large portion of the patient population. These advanced treatments, while promising, are often priced at a premium due to the complexity of development and manufacturing processes. As a result, patients in low- and middle-income countries, or those without adequate healthcare coverage, may struggle to access these therapies. The long-term nature of GA, which often requires ongoing treatment to manage disease progression, further exacerbates the financial burden on both patients and healthcare systems. This high cost can delay the widespread adoption of new therapies, hindering market growth and limiting the overall impact of innovations in GA treatment. Thus, addressing the affordability of these treatments is essential for ensuring broader access and market expansion.    

  • Limited Treatment Options

Limited treatment options represent a significant challenge in the Global Geographic Atrophy (GA) market. At present, there are no FDA-approved therapies specifically designed for GA, and existing treatments mainly focus on slowing the progression of the disease rather than offering a cure. Although there is ongoing research into promising therapies like complement inhibitors, their long-term effectiveness has yet to be proven. This lack of effective treatments leaves many patients with few choices, which not only negatively impacts their quality of life but also hinders market growth. Additionally, the complexity of GA, which is driven by multiple factors such as genetic and environmental influences, makes it challenging to develop a one-size-fits-all solution. This adds another layer of difficulty to the development of effective therapies. As a result, the slow pace of therapeutic advancements continues to be a major barrier, keeping GA as an unmet medical need and limiting the overall growth potential of the market.

Geographic Atrophy Market Scope

The market is segmented on the basis of drug class, route of administration, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Anti-VEGF (Vascular Endothelial Growth Factor) Agents
  • Complement Pathway Inhibitors
  • Cell and Gene Therapies
  • Other Therapeutics

Route of Administration

  • Intravitreal
  • Oral
  • Others

Gender

  • Male
  • Female

End User

  • Hospitals
  • Ophthalmic Clinics
  • Homecare Settings

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Geographic Atrophy Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, drug class, route of administration, gender, end user, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to its well-established healthcare systems, high prevalence of age-related macular degeneration (AMD), and significant investments in research and development for innovative therapies.

Asia-Pacific is expected to be the fastest growing due to the region's rapidly aging population, increasing awareness of eye health, and growing access to advanced healthcare technologies and treatments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Geographic Atrophy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Geographic Atrophy Market Leaders Operating in the Market Are:

  • Apellis Pharmaceuticals, Inc. (U.S.)
  • Regeneron Pharmaceuticals, Inc.  (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Biogen Inc. (U.S.)
  • Gyroscope Therapeutics Limited (UK)
  • Kodiak Sciences Inc. (U.S.)
  • Lineage Cell Therapeutics, Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Outlook Therapeutics, Inc. (U.S.)
  • Iveric Bio, Inc. (U.S.)
  • Astellas Pharma Inc. (Japan)
  • Adverum Biotechnologies, Inc. (U.S.)
  • Alkeus Pharmaceuticals, Inc. (U.S.)
  • Annexon, Inc. (U.S.)
  • Nanoscope Therapeutics, Inc. (U.S.)
  • Clearside Biomedical, Inc. (U.S.)
  • ReNeuron Group plc (UK)
  • Ocugen, Inc. (U.S.)

Latest Developments in Global Geographic Atrophy Market

  • In November 2024, Astellas Pharma Inc. announced that the FDA issued a Complete Response Letter (CRL) on November 15, 2024, regarding the supplemental New Drug Application (sNDA) for IZERVAY (avacincaptad pegol) for treating geographic atrophy (GA) due to age-related macular degeneration (AMD). This feedback provides Astellas with critical insights to refine its application and strengthen future regulatory submissions
  • In October 2024, Annexon, Inc. announced that it will present new analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA) at the AAO 2024 annual meeting and the Eyecelerator conference on October 17-21, 2024, in Chicago. This will increase the company’s exposure in the ophthalmology field and potentially attract more interest in its GA therapies
  • In September 2024, Boehringer Ingelheim and CDR-Life announced positive Phase I results for BI 771716, an investigational antibody fragment aimed at preserving vision in people with geographic atrophy (GA). This success could enhance the company's position in the GA market and drive further development of innovative treatments
  • In July 2024, Ocugen, Inc. announced the completion of dosing in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a novel gene therapy for geographic atrophy (GA). This progress positions the company for potential breakthroughs in GA treatment and strengthens its pipeline of innovative therapies
  • In May 2024, Johnson & Johnson announced eight company-sponsored presentations at the ARVO 2024 Annual Meeting in Seattle, including two oral presentations on genetic testing for inherited retinal diseases (IRDs) and the use of deep-learning algorithms to measure precursors of geographic atrophy (GA). These presentations will enhance the company's thought leadership in ophthalmology and highlight its advancements in eye disease research

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on Segmentation, By Drug Class (Anti-VEGF (Vascular Endothelial Growth Factor) Agents, Complement Pathway Inhibitors, Cell and Gene Therapies, Other Therapeutics), Route of Administration (Intravitreal, Oral, Others), Gender (Male, Female), End User (Hospitals, Ophthalmic Clinics, Homecare Settings), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Industry Trends and Forecast to 2032 .
The Global Geographic Atrophy Market size was valued at USD 1.78 USD Billion in 2024.
The Global Geographic Atrophy Market is projected to grow at a CAGR of 9.6% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
Testimonial
a